ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Big Week for Earnings: Apple Headlines a Packed Schedule

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Today brings the first major print. REGN reports this morning, with its Q3 earnings call already underway at 8:30am ET. The $80bn biomaker faces investor scrutiny over its Dupixent franchise outlook.

Sunday evening kicks off a critical run for tech. AAPL reports Monday, November 2, with a call at 5pm ET. At a $5 trillion market cap, it is the single most watched event of the week. MAR and IDXX also report Monday morning.

Tuesday brings AMGN, BKNG and PGR. Progressive is one to watch: its October premium data is already public, giving analysts an unusually clear read ahead of the call. RACE also reports Tuesday. European car registration data tracked by ORTEX Alt Data shows that metric running 75% below the same quarter last year, a weak leading signal for the print.

Wednesday is dense. QCOM, COR, ALB and CPAY all report. Qualcomm's handset chip outlook will be watched closely given recent smartphone demand signals.

Thursday closes the week with AMGN, MCHP, ALL and AKAM. No IPOs are scheduled in the next seven days per available data.

The Russell 2000 December review ranks on today's close. ORTEX Index Rebalance Radar shows VSAT deletion odds jumped to 80% overnight, with a potential $1.3bn forced sale equal to 8.4 days of volume. Twist Bioscience sits at the same 80% deletion probability, with $1.5bn of forced selling at stake. The announcement falls on 13 November.

Stocks in this article

How this article was generated

Generated
30 Oct 2026, 04:31
Prompt version
v1.0
Data sources
EarningsAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.